Pandiella A - Search Results

1

Circulating DNA and Survival in Solid Tumors.

Ocaña A, Díez-González L, García-Olmo DC, Templeton AJ, Vera-Badillo F, José Escribano M, Serrano-Heras G, Corrales-Sánchez V, Seruga B, Andrés-Pretel F, Pandiella A, Amir E. Ocaña A, et al. Among authors: pandiella a. Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):399-406. doi: 10.1158/1055-9965.EPI-15-0893. Epub 2015 Nov 24. Cancer Epidemiol Biomarkers Prev. 2016. PMID: 26604269 Review.

2

Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance.

Ocaña A, Cruz JJ, Pandiella A. Ocaña A, et al. Among authors: pandiella a. Am J Clin Oncol. 2006 Feb;29(1):90-5. doi: 10.1097/01.coc.0000190274.00570.0a. Am J Clin Oncol. 2006. PMID: 16462510 Review.

3

Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer.

Cruz JJ, Ocaña A, Del Barco E, Pandiella A. Cruz JJ, et al. Among authors: pandiella a. Ann Oncol. 2007 Mar;18(3):421-30. doi: 10.1093/annonc/mdl175. Epub 2006 Jul 27. Ann Oncol. 2007. PMID: 16873430 Free article. Review.

4

Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer.

de Alava E, Ocaña A, Abad M, Montero JC, Esparís-Ogando A, Rodríguez CA, Otero AP, Hernández T, Cruz JJ, Pandiella A. de Alava E, et al. Among authors: pandiella a. J Clin Oncol. 2007 Jul 1;25(19):2656-63. doi: 10.1200/JCO.2006.08.6850. J Clin Oncol. 2007. PMID: 17602072

5

An update into the pathophysiological role of HER2 in cancer: therapeutic implications.

Ocaña A, Pandiella A. Ocaña A, et al. Among authors: pandiella a. Clin Transl Oncol. 2007 Sep;9(9):543-4. doi: 10.1007/s12094-007-0100-x. Clin Transl Oncol. 2007. PMID: 17921099 No abstract available.

6

Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options.

Ocaña A, Pandiella A. Ocaña A, et al. Among authors: pandiella a. Clin Cancer Res. 2008 Feb 15;14(4):961-70. doi: 10.1158/1078-0432.CCR-07-1630. Clin Cancer Res. 2008. PMID: 18281527 Review.

7

Neuregulins and cancer.

Montero JC, Rodríguez-Barrueco R, Ocaña A, Díaz-Rodríguez E, Esparís-Ogando A, Pandiella A. Montero JC, et al. Among authors: pandiella a. Clin Cancer Res. 2008 Jun 1;14(11):3237-41. doi: 10.1158/1078-0432.CCR-07-5133. Clin Cancer Res. 2008. PMID: 18519747 Review.

8

Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.

Esparís-Ogando A, Ocaña A, Rodríguez-Barrueco R, Ferreira L, Borges J, Pandiella A. Esparís-Ogando A, et al. Among authors: pandiella a. Ann Oncol. 2008 Nov;19(11):1860-9. doi: 10.1093/annonc/mdn406. Epub 2008 Jul 17. Ann Oncol. 2008. PMID: 18641009 Free article.

9

Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target.

Montero JC, Ocaña A, Abad M, Ortiz-Ruiz MJ, Pandiella A, Esparís-Ogando A. Montero JC, et al. Among authors: pandiella a. PLoS One. 2009;4(5):e5565. doi: 10.1371/journal.pone.0005565. Epub 2009 May 15. PLoS One. 2009. PMID: 19440538 Free PMC article.

10

Novel tyrosine kinase inhibitors in the treatment of cancer.

Ocana A, Serrano R, Calero R, Pandiella A. Ocana A, et al. Among authors: pandiella a. Curr Drug Targets. 2009 Jun;10(6):575-6. doi: 10.2174/138945009788488378. Curr Drug Targets. 2009. PMID: 19519359 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

259 results

Search Page